Pancreatic cancer is one of the most aggressive and challenging malignancies, characterized by rapid progression and poor prognosis. It commonly originates in the exocrine cells of the pancreas and is often diagnosed at an advanced stage due to the lack of early symptoms. Risk factors include smoking, chronic pancreatitis, diabetes, obesity, family history, and genetic predisposition.

Early pancreatic cancer may cause subtle symptoms such as indigestion, mild abdominal discomfort, or unexplained weight loss. As the disease advances, patients may experience jaundice, severe abdominal or back pain, appetite loss, fatigue, and digestive disturbances. Due to late presentation, medical oncology plays a crucial role in disease management.

Systemic chemotherapy is the primary treatment modality for most pancreatic cancer patients. It may be administered before surgery to reduce tumor size, after surgery to lower recurrence risk, or as definitive treatment for advanced or metastatic disease. Combination chemotherapy regimens are commonly used to improve response rates and survival outcomes.

Research advances have led to improved treatment sequencing and supportive care strategies. While targeted therapy and immunotherapy have limited roles in pancreatic cancer, ongoing molecular testing helps identify select patients who may benefit from novel or trial-based treatments.

For advanced pancreatic cancer, medical oncology focuses on disease control, symptom relief, and quality of life. Pain management, nutritional support, and psychological care are essential components of treatment due to the significant symptom burden associated with this disease.

In Dubai and the UAE, pancreatic cancer care adheres to international oncology protocols, emphasizing multidisciplinary management and early integration of supportive oncology services. Timely access to systemic therapy and comprehensive care pathways are critical in improving patient outcomes.